Form 4: Relay Therapeutics Executive Granted Stock Options
SEC Form 4 Filing
Peter Rahmer, Chief Corporate Development Officer at Relay Therapeutics, was granted stock options for 275,000 shares.
Summary
- Peter Rahmer, Chief Corporate Development Officer of Relay Therapeutics, was granted stock options for 275,000 shares.
- The options have an exercise price of $4.45 per share.
- The options vest in 16 equal quarterly installments starting after January 10, 2025, contingent on continued service with the company.
- The options expire on January 9, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no indications of negative sentiment.
Positives
- The granting of stock options aligns the executive's interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Risks
- The value of the options is dependent on the future performance of the company's stock price.
- The executive must remain employed by the company to fully vest the options.
Future Outlook
The vesting of the stock options is contingent on the executive's continued service with the company.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Comparison to Industry Standards
- Stock option grants are a standard practice for incentivizing executives in the biotech industry.
- The vesting schedule of 16 equal quarterly installments is a typical approach to ensure long-term commitment.
- The exercise price of $4.45 is specific to the company's stock price at the time of the grant.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it incentivizes management to increase the company's value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of the stock option grant and start of the vesting period. |
| 01/09/2035 | Expiration date of the stock options. |
| 01/14/2025 | Date the form was signed. |
Keywords
stock options, executive compensation, insider trading, RLAY, Relay Therapeutics, Peter Rahmer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.